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Abstract
The purpose of this study was to investigate isokinetic strength, quality of life, range of 
motion, and calf circumference for patients with acute Achilles tendon rupture treated non- 
operatively with accelerated functional rehabilitation with or without Autologous 
Conditioned Plasma (ACP®).
We used a cohort of patients (n=34) from a published randomized trial to serve as our 
historical control group. We recruited 51 consecutive patients and administered two ACP® 
injections during the first four weeks post injury.
The mean between groups difference in plantar flexion strength (injured/uninjured) at one 
year post injury was 2.9% (95% Cl -13.6 to 7.8), p = 0.6 and -0.3% (95% Cl -13.6 to 13.0), p 
= 1.0 at 30°/s and 607s respectively. All secondary outcomes were also not different.
The addition of ACP to a non-operative treatment protocol with accelerated functional 
rehabilitation does not provide better outcomes at one year post Achilles tendon rupture.
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1 Chapter 1: Introduction
Rupture of the Achilles tendon is one of the most common tendon injuries in the adult 
population. The incidence of Achilles tendon injury is increasing as aging adults continue 
to participate in high demand sports 44 S4' 74 such as basketball, racquet sports, soccer, etc. 
There is debate about the most effective treatment of Achilles tendon ruptures; some 
arguing for operative repair while others argue for a non-operative approach. In a 
randomized clinical trial of 144 patients, Willits et al (2010)112 found that the strength, 
range of motion and patient-reported function in 72 patients treated non-operatively were 
similar to outcomes reported by 72 patients who were treated with operative repair. In a 
systematic review of the literature, they found similar conclusions whenever the non­
operative treatment entailed early mobilization110.
Recently platelet-rich plasma (PRP) was introduced as a new treatment option for 
orthopedic injuries22' 24' 24 72 ss. PRP is defined as a concentration of platelets in plasma 
that is greater than the baseline concentration67. Platelets are a type of white blood cell 
that contains more than 30 bioactive proteins, many of which have a fundamental role in 
haemostasis or tissue healing". The intended purpose of PRP is to create an optimal 
healing environment by isolating the plasma components from an individual's blood and 
injecting it at the site of injury.
Platelet rich plasma (PRP) has many names throughout the literature; autologous 
conditioned plasma (ACP®), platelet enriched plasma (PeRP), platelet-rich concentrate 







releasate2' 67' 90. The variation in name is dependent on the concentration of plasma, the 
preparation system, the addition of anticoagulants, or the addition of activating agents. In 
our study we used autologous conditioned plasma (ACP®) as prepared by the Arthrex 
Bio Systems™ (Arthrex, Inc., Naples, Florida).
On February 17, 2009 the New York Times reported that two of the Pittsburgh Steelers 
football players had used their own blood (PRP) to accelerate the healing time of their 
injuries (a calf muscle strain in one athlete and a medial collateral ligament sprain in the 
other). According to the article, these injuries should have kept these athletes sidelined 
for the Super Bowl game. Following the injection however, both athletes played in the 
game and the team won the NFL championship.
A recent systematic review by Taylor et al (2011) , evaluated outcomes following the
use of PRP for the treatment of tendon and ligament injuries in vivo and in humans. The 
authors found three randomized studies; three prospective cohort studies; and seven case- 
reports or case-control studies that met their inclusion criteria. Eight of these studies 
reported favorable outcomes for pain, functional scores, range of motion and return to 
activity with the use of PRP, (one of these was a randomized trial). The other studies 
reported no significant benefits to the use of PRP.
With respect to studies that have evaluated the use of PRP for Achilles tendon tears, 
Sanchez et al (2007)Sii published a case-control study where six athletes with complete 
Achilles tendon tears underwent open suture repair augmented with a preparation rich in 
growth factors (PRGF). Range of motion, functional recovery, complications, and cross- 









had the same injury and received the same treatment with the exception of the PRGF 
injection. Athletes receiving PRGF recovered their ankle range of motion earlier (7 +/- 2 
weeks vs 11 +/- 3 weeks, p = 0.03) (Mean diff. = 4; Cl 95% 0.72 to 7.28, p = 0.02), 
showed no wound complication, were permitted by their surgeon to take up gentle 
running more quickly ( 11 +/- 1 weeks vs 18 +/- 3 weeks, p = 0.04) (Mean diff. = 7; Cl 
95% 4.12 to 9.88 p < 0.01), and to resume training activities ( 14 +/- 0.8 weeks vs 21 +/- 3 
weeks, p < 0.01 ) (Mean diff = 7.0; Cl 95% 4.18 to 9.82 p < 0.01).
To date, there has been no study investigating the effects of applying ACP® to an acute 
complete tendon tear treated non-operatively with accelerated functional rehabilitation. 
Thus, this study is a prospective cohort study with historical control group to compare the 
one year outcomes following non-operative treatment of patients with an acute Achilles 





2 Chapter 2: Literature Review
2.1 Functional Anatomy of the Achilles Tendon
2.1.1 Histology of the Achilles Tendon
Tendons are anatomic structures interposed between muscles and bones transmitting the 
force created in the muscle to bone, and, in this way, making joint movement possible46. 
Tendons are stiff and resilient, with high tensile strength: they can stretch up to 4% 
before damage23. Tenocytes (specialized fibrocytes) and tenoblasts comprise 90-95% of 
the cellular elements of the tendon, with chondrocytes, vascular cells, synovial cells and 
smooth muscle cells forming the remaining 5-10%23. Tenocytes and tenoblasts produce 
collagen and elastin, and these in turn are organized in a complex hierarchical scheme to 
form the tendon proper46. Tendons consist of collagen (mostly type I collagen) and elastin 
as part of the extracellular matrix, embedded in a proteoglycan-water matrix with 
collagen accounting for 65-80% and elastin approximately 1-2% of the dry mass of the 
tendon46.
A fine sheath of connective tissue called endotenon invests each collagen fiber and binds 
fibers together. A bunch of collagen fibers forms a primary fiber bundle, and a group of 
primary fiber bundles forms a secondary fiber bundle. A group of secondary fiber 
bundles, in turn, forms a tertiary bundle, and the tertiary bundles make up the tendon46. 
The entire tendon is surrounded by a fine connective tissue sheath called epitenon46. The 
epitenon in turn is surrounded by paratenon. The paratenon and epitenon are separated by 









2.1.2 Muscles contributing to the Achilles tendon
Cohen (2009)|,, describes the Achilles tendon as the largest and most powerful tendon in 
the ankle, while Doral et al (2009)25 adds that it is the strongest and thickest tendon in the 
human body. It is also one of the most commonly torn tendons . The gastrocnemius and 
soleus muscle tendons join in their distal portions to form the Achilles tendon (Figure
l ) 19’33.
Figure 1 Muscles of the Achilles tendon
Medical Illustration Copyright © 2011 Nucleus Medical Media, All rights reserved, www.nucleusinc.com
19 25 33The gastrocnemius is a fusiform muscle composed of medial and lateral heads ’ ’ .
The gastrocnemius is the most superficial muscle of the dorsal aspect of the lower leg and 
gives the calf its characteristic bulge25. The origin of the gastrocnemius is from the 
posterior aspect of the distal femoral condyles. Both heads of the gastrocnemius cross the 
knee joint25. The gastrocnemius is considered a flexor of the knee and a plantar flexor of
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the ankle, and produces the maximal moment of force during contraction with the ankle 
plantar flexed and the knee extended. The main function of the gastrocnemius muscle is 
to supply power for propulsion of the body forward during gait19 ".
The solcus muscle has a complex multipennate architecture19. Two separate 
compartments, a bipennate anterior compartment and a unipennate posterior 
compartment, can be identified within the soleus muscle'9. The soleus muscle originates 
from the posterior aspects of the tibia and fibula at their proximal ends. It acts only on 
the ankle joint and can be palpated on either side of the gastrocnemius when the subject 
stands on their tiptoes '. The soleus muscle as part of the gastroc-soleus complex and 
produces the maximal force during contraction with the ankle plantar flexed and the knee 
flexed. The soleus is a postural muscle that also acts as a peripheral vascular pump19.
2.1.3 Tendinous formation of the Achilles tendon
In their distal aspects, both the gastrocnemius and the soleus muscles form an 
aponeurosis, from each of which originates a tendon19. These two tendons freely glide 
independently before they coalesce into the Achilles tendon, approximately 5 to 6 cm 
proximal to the calcaneal insertion19' 2'. The tendinous components of these two muscles 
are variable. The gastrocnemius component is longer (11-26 cm) than that of the soleus 
(3-11 cm)92. Fibers from the medial head of the gastrocnemius muscle pass laterally and 
posteriorly, whereas the fibers from the lateral head of the gastrocnemius muscle reach 
the anterior surface of the tendon100. Szaro et al (2009)'°° also found that the deep part of 












the soleus muscle. The superficial layer of the tendon is formed by the fibers from the
i oomedial head of the gastrocnemius and soleus muscles .
The superficial crural fascia also contributes fibers to the Achilles tendonl9. The Achilles 
tendon is larger at the insertion on the inferior half of the posterior calcaneal surface19.
1525 100The average length of the Achilles tendon is 15cm and ranges from 11 to 26cm " ’
The mean width of the Achilles tendon is 6.8cm (4.5 -  8.6cm) at its origin, gradually 
becoming thinner at the midsection being 1.8cm (1.2 -  2.6cm)4. It then becomes rounded 
until approximately 4cm above the calcaneus before expanding" ’ . The mean width of
the Achilles tendon is 3.4cm (2.0 -  4.8cm) at its insertion to the midpoint of the posterior 
surface of the calcaneus4.
The Achilles tendon is rounded proximally and relatively flat distally19. Approximately 
12 -  15cm proximal to its insertion (at about the level where the soleus contributes fibers 
to the Achilles tendon), rotation begins and becomes more marked in the distal five to six 
centimeters19' 23. Rotation of the fibers from the Achilles tendon has been described as 
twisting 90 degrees counterclockwise toward the insertion into the calcaneal tuberosity33. 
The degree of rotation of the tendon is variable, ranging between 30 to 150 degrees19.
2.1.4 Blood and Nerve Supply to the Achilles Tendon
The Achilles tendon receives its blood supply from three regions. It comes from the 
intrinsic vascular systems at (1) the musculotendinous junction, (2) the osteotendinous 
junction, and from the extrinsic segmental vascular system through (3) the paratenon 





the main blood supply to the middle portion of the tendon19. This supply comes through a 
series of venicula, which function as passageways for blood vessels to reach the tendon19. 
A recurrent branch of the posterior tibial artery supplies the proximal part of the tendon, 
whereas the distal part is vascularized by the rete arteriosum calcaneare and supplied by 
the fibular and posterior tibial arteries' l9. There is an area of relative avascularity in the 
Achilles tendon 2-6 cm above its insertion ' . Dorai et al (2009) suggests that it is due 
to the structure of the blood supply that there is a relatively hypovascular area in the mid- 
I portion of the tendon where most problems occur.
The Achilles tendon is supplied by nerves from the attaching muscles and by small 
fasciculi from cutaneous nerves, in particular the sural nerve84 with a smaller supply from 
the tibial nerve2s.
2.1.5 Related structures
The site at which a tendon, ligament or joint capsule attaches to bone is known as an 
enthesis94. This attachment is often part of a collection of tissues jointly called an 
‘enthesis organ’. The purpose of this organ is to reduce stress concentration at the hard- 
soft tissue interface94. The insertion of the Achilles tendon is part of such an ‘enthesis 
organ’. The organ also includes opposing sesamoid and periosteal fibrocartilages, a bursa 
and Kager’s fat pad.
There is a retrocalcaneal bursa that lies deep and just proximal to the insertion of the 
Achilles tendon, between the posterior calcaneal tuberosity and the tendon19. Superficial 







composed of synovium and provides lubrication to assist with tendon gliding and to 
minimize tendon irritation19.
The Achilles tendon is surrounded by a paratenon which is a double-layered sheath 
composed of an inner, visceral layer and an outer, parietal layer. The tendon has no true 
synovial sheath19. Nerves and blood vessels run through the paratenon, which is the main 
blood supply to the middle portion of the tendon19. Deep to the paratenon, the Achilles 
tendon is surrounded by the epitenon, a fine, smooth connective tissue sheath. The inner 
surface of the epitenon is continuous with the endotenon, which binds the collagen fibers 
and fiber bundles together and provides the neural, vascular, and lymphatic supply to the 
tendon*4.
2.2 Achilles Tendon Rupture
2.2.1 Epidemiology
The following studies summarize the incidence and patient population associated with 
acute Achilles tendon ruptures.
Leppilahti et al (1996)S4 determined the incidence of Achilles tendon rupture in the city 
of Oulu, Finland over a 16 year period (1979 to 1994). During this period 111 ruptures 
occurred in 110 individuals. The incidence increased from two ruptures per 10s 
inhabitants in 1979 to 1986, to 12 in 1987 to 1994. The annual incidence after 1985 
increased more in men (94) than in women (17). There was also a greater rise in 
incidences in sports-related injuries (90) than non-sports-related injuries (21). The peak
9
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age-specific annual rupture incidence was in the age group 30 to 39 years (r = 0.74, p <
0 .01).
Moller et al ( 1996)74 researched the incidence of Achilles tendon rupture in the city of 
Malmo, Sweden from 1987 to 1991. They found 153 diagnosed cases. They found the 
highest incidence in the age group of 30 to 39 with an incidence of 30.4 per 100, 000 
inhabitants, followed by the 40 to 49 age group with an incidence of 26.2 per 100, 000 
inhabitants. The average age of men was 42 (20-80) years and of women 52 (25-80) years 
(p < 0.01). Sports injuries (98) were almost twice as common as other injuries (55), and 
incidence was greater in men (132) than women (21), especially in the sports injuries 
group (men = 97, women = 7). Badminton, soccer and tennis were most common 
amongst sports injuries.
Houshian et al ( 1998)40 studied the incidence of Achilles tendon ruptures in a Danish 
county from 1984-1996. There were 718 ruptures, 544 men (75.8%) and 174 women 
(24.2%). The average age was 42.1 years (3-82) and 62% were between 30^19 years. 
74.2% of the ruptures were sport-related and 89% of these occurred in ball and racket 
games. The annual incidence of Achilles tendon ruptures increased from 18.2 per 100, 
000 inhabitants in 1984 to 37.3 per 10s in 1996 (r = 0.63, p < 0.05). The peak incidence 
in sport-related ruptures occurred in the age group 30-49 years, but ruptures not related 
to sport occurred in older patients with a peak incidence in those 50-59 years.
Jozsa et al (1989)44 completed a review of 749 patients who had 832 various tendon 
ruptures treated surgically, 292 cases of which were Achilles tendon ruptures, between 









Achilles tendon rupture. They found that 59% of Achilles tendon ruptures occurred in 
recreational sports activities in contrast to two percent in other tendon ruptures (p <
I 0.01). The mean age for patients with Achilles tendon ruptures was 35.2 years, and 50.7
years in those with other ruptures (p < 0.01). Amongst the patients with Achilles tendon 
ruptures, 82.9% were male, and 18.1% were female.1 Summary: Achilles tendon ruptures are most common in the male population, those 
aged between 30 and 39, and are more likely to occur during recreational sports activities. 
There also appears to be an increase in incidence over those time periods studied.
2.2.2 Mechanism of Injury
Sudden force application (resulting in a larger than usual force being applied rapidly to 
I the tendon), typically involving eccentric muscle contraction, may lead to muscle or
tendon in ju ryP atien ts with Achilles tendon ruptures usually report a sudden, painful
39pop or snap in their calf with subsequent weakness and gait disturbances .
Wapner (2011)109 describes the mechanism of injury for an Achilles tendon rupture as 
occurring at a moment of deceleration. It often occurs when the gastrocnemius muscle 
forcibly retracts, as when one lands on the ground after going up for a rebound in 
basketball, causing a sudden and unexpected dorsi flexion of the ankle. They also occur 
while pushing off with the knee extended, such as in tennis when an individual lunges for 
a shot. Another mechanism is with a sudden violent dorsi flexion force on a plantar 
flexed foot. All of these mechanisms result in an eccentric muscle contraction by the 













traumatic ruptures occur because the force exerted on the suddenly rapidly loaded tendon 
exceeds the tendon’s tensile strength109.
I 2.2.3 Causes of and Predisposition to Rupture
Chen et al (2009)16 proposes that multiple factors are involved in the pathogenesis of 
tendon rupture. Possible risk factors of Achilles tendon rupture apart from direct trauma, 
include ageing, underlying tendon degeneration (inflammatory, microtrauma), the use of 
corticosteroids -  (local/systemic), and the use of fluoroquinolones6' 49' 47' 59,71' 98.
Josza et al (1997)43 found degenerative changes in the tendon, like tendinitis, as a 
predisposing factor to Achilles tendon rupture, which others16 have suggested is due to 
the hypovascular region found in the tendon. Chronic tendinitis as a result of overuse or 
overload of the Achilles tendon may consist of microtears of the tendon which may lead 
to injury16. A watershed region of decreased vascularity has been noted in a number of 
studies, located approximately two to six centimeters proximal to the calcaneal insertion 
of the tendon, and is a common location of Achilles tendon lesions10' 91. The use of 
fluroquinolone antibiotics has been associated with Achilles tendon rupture through an 
unknown mechanism ’ .
Chazan ( 1998)15 proposes that the structure of the Achilles tendon as it twists from 
proximal to its distal insertion may predispose it to rupturel5. Heckman et al (2009)41 
suggest that a cavus foot or a flat foot with excessive pronation, as well as malalignment 
factors above the ankle, such as genu varum, can also contribute to increased stress on the 






injuries are frequently encountered in individuals who participate in strenuous physical 
activities that involve repetitive, eccentric, impact loading and jumping34.
2.2.4 Diagnosis and Clinical Presentation
Patients with acute Achilles tendon rupture describe the sensation as feeling like they had 
been hit in the back of the ankle or calf. This is followed by intense pain, and the inability 
to bear weight due to weakness of the calf and inability to plantar flex the ankle. The 
Simmonds’ test, also known as the Thompson test, is a gross screening examination for 
an Achilles tendon rupture often used as a diagnosis for complete Achilles tendon 
rupture1' ' 101. The patient lies prone on the examination table with the feet and ankles 
positioned over the edge of the table. In a person with an intact Achilles tendon, the foot 
should move into plantar flexion when you squeeze the calf muscles bilaterally. No 
movement in the foot indicates a rupture". Ultrasound has also been commonly used as a 
diagnostic tool in the evaluation of acute Achilles tendon rupture12.
The foot on the affected leg is maintained in a plantar flexed position when the patient 
sits on the examination table. Patients often present with swelling in the posterior ankle, 
foot and toes. Subjectively reported pain levels can be variable11' 26.
Harris et al (2006)3S describes full thickness tears or rupture as that which involves the 
entire cross-section of the tendon with a gap between the retracted torn tendon ends. The 




2.2.4.1 Assessment of Achilles Tendon Rupture
Maffulli (1998)ss completed a study to determine the sensitivity, specificity, and positive 
and negative predictive values of several clinical diagnostic tests of subcutaneous 
Achilles tendon ruptures, including: palpation for the presence of a gap; calf squeeze for 
presence of plantar flexion of the ankle; Matles test for comparison of the amount of 
plantar flexion in the affected leg when compared with the unaffected while patient lies 
prone and both knees are flexed to 90°; Copeland test which looks for a rise in pressure 
around the calf using a sphygmomanometer and passively dorsi flexing the ankle with the 
knee in 90° flexion; and the O'Brien test which looks at the movement of a needle placed 
in the tendon which is then passively dorsi or plantar flexed. The study included 174 
patients with complete rupture and 28 with suspected but no actual tears. They found the 
Matles test and calf squeeze test (Thompson test) to be significantly more sensitive than 
the other tests (0.022 < p < 0.05).
Leppilahti et al (1998)53 compiled a clinical scoring scale which was the first 
standardized protocol for evaluation of repaired Achilles tendon ruptures. It consists of 
subjective assessment of the symptoms (pain, stiffness, muscle weakness, footwear 
restrictions), clinical evaluation of ankle range of motion, overall patient satisfaction, and 
isokinetic calf muscle strength (plantar and dorsi flexion). The authors applied the system 
to a large series of patients, analyzing the prognostic factors related to the results at 3.1 
years after surgery with a six week cast immobilization post surgery. Their study 
included 101 patients, 21 of which were professional athletes and 70 of which were 
recreational athletes. Authors found patient characteristics associated with unsatisfactory 







return to physical exercise. An older age and later return to physical activity were 
associated with unsuccessful or lower overall results.
Martin et al (2005)65 completed a review of the existing range-of-motion measurement 
literature related to ankle dorsi flexion and plantar flexion to determine whether the 
reliability of ankle range-of-motion measurements can be defined, how the characteristics 
of the study population or clinician affect reliability, and the level of responsiveness for 
these measures. Eleven articles met their inclusion criteria. Authors were unable to pool 
results for the studies as the methods used for each varied greatly. Authors did find 
evidence for intra-rater reliability for plantar and dorsi flexion, as well as inter-rater 
reliability for ankle dorsi flexion. Authors also concluded that the responsiveness of ankle 
joint range of motion measurements is uncertain and requires further studies using patient 
populations.
Moller et al (2005)75completed a study to investigate the reliability of different methods 
used for isokinetic testing of calf muscle strength and endurance. Ten healthy subjects 
volunteered for the study and were tested for isokinetic plantar and dorsi flexion strength 
using a dynamometer in three positions: seated with the hip at 110° flexion and the knee 
at 90° flexion, seated with the hip and knee at 90° flexion, and supine with hip and knee 
at neutral (full extension). An endurance test was performed with a test device for the 
standardized counting of heel raises. Passive and active ankle range of motion was 
measured with a goniometer, calf circumference with a tape measure, and tendon width 
was measured with a vernier caliper. The ICCs for plantar flexion in position one (right 
and left side) were 0.37-0.95. The corresponding values in position two (right and left 








flexion ranged from 0.61-0.91. The test-retest reliability of the isokinetic measurements 
of dorsi flexion, measured as ICC, in position one (right and left side) was 0.34-0.96 .
The corresponding values in position two (right and left side) were 0.00-0.83. The 
reliability expressed as ICC was found to be 0.78-0.84 for the endurance test, 0.97-0.98 
for the calf circumference, 0.84-0.87 for the tendon width and 0.71-0.91 for the range of 
motion. Authors concluded that the test-retest reliability was acceptable for all the 
methods that were employed.
In 2007, Nilsson-Helander et al79 developed and evaluated the Achilles tendon rupture 
score (ATRS). It is a patient-reported instrument for measuring outcome after treatment 
for Achilles tendon rupture which includes 10 questions related to strength, fatigue, 
stiffness, pain and activities. The ATRS was tested for validity, structure, and internal 
consistency (Cronbach's alpha) on 82 patients and 52 healthy persons. Authors 
performed a correlation analysis with the two validated foot/ankle/Achilles tendon scores, 
the Foot and Ankle Outcome Score (FAOS) and the Swedish version of the Victorian 
Institute of Sports Assessment-Achilles questionnaire (VISA-A-S). Structure was 
evaluated with factor analysis. Test-retest reliability was evaluated on 43 patients. The 
ATRS responsiveness was tested on 43 patients by calculating the effect size. The total 
score for the patients ranged from 17 to 100 with a mean of 77 ± 21.4. A significantly (p 
< 0.01) higher total score was found for the healthy subjects, ranging from 94 to 100 with 
a mean of 99.8 ±1.1. The ATRS correlated significantly (p < 0.01) with all subscales of 
the FAOS (r = 0.60-0.84) and the VISA-A-S (r = 0.78). The factor analysis gave one 




alpha. The test-retest produced an intraclass correlation coefficient of 0.98. The tests for 
responsiveness showed an effect size between 0.87 and 2.21.
2.3 Treatment of the Achilles Tendon Rupture
2.3.1 Tendon Healing
There are three phases in tendon healing, and these phases overlap as the tissue completes 
its healing. The first phase is known as the inflammatory phase and comprises 
recruitment of inflammatory cells, phagocytosis of necrotic materials release of 
vasoactive factors, initiation of angiogenesis, and stimulation of tenocyte proliferation113.
O ' i  #This is also the phase where platelet activation '  takes place through the action of the 
growth factors.
82After a few days, the proliferative phase begins where cells proliferate and differentiate . 
Fibroblasts become the predominant cell type during this phase {Maffulli 2000} as they 
align themselves perpendicular to the long axis of the tendon. Synthesis of type III 
collagen peaks during this stage, which lasts for a few weeks . Production of collagen 
type I gradually takes over, and the repair callus reaches its largest size .
After approximately six to 10 weeks, the maturation or remodeling phase begins with 
decreased cellularity and decreased collagen and glycosaminoglycan synthesis, and 
gradual change of fibrous tissue to scar-like tendon tissue over the course of one year 
{Olivia, Zafar}. During the latter half of this stage, tenocyte metabolism and tendon 
vascularity decline113. Collagen type III is reabsorbed and replaced to produce better
organization, and cross-linking increases. Finally, the callus transverse area gradually
82decreases as the mechanical tissue properties improve .
2.3.2 History of the Treatment of Achilles Tendon Ruptures
The first description of the Achilles tendon was by Ambroise Pare in the early 1900’s49. 
Polaillon performed the first reported repair of an acute Achilles tendon rupture in 1888, 
and the first comparative study comparing operative versus non-operative treatment was 
published by Qenu and Stoianovich in 192949. Up until the early part of the 20lh century 
this condition had been managed non-operatively, but following a particular study by 
Arner and Lindholm (1959)6, operative treatment became the accepted form of 
management47. This study however, reported a complication rate of around 24%, which 
lead a number of researchers to explore the approach of non-operative treatment47.
2.3.3 Operative Treatment
Operative repair of the ruptured Achilles tendon has been the preferred treatment by 
surgeons as some studies have shown a significantly lower re-rupture rate when 
compared to non-operative treatment ’ ' . However, in these studies patients in the 
non-operative groups were treated with below knee casting for six to eight weeks More 
recently the literature has shown that early functional rehabilitation in a below knee 
orthosis can drastically reduce the rates of re-rupture72 " 2, resulting in equivalent re­
rupture rates between operative and non-operative treatment.
Operative treatment of the acute Achilles tendon rupture can be done with an open or 








ends and an assessment of tendon length, but may disrupt the blood supply to the tendon 
by damaging the paratenon48. The pereutaneous technique minimizes this complication, 
but has been associated with sural nerve injury and a higher re-rupture rate™ ?7. In a 
review by Khan et al (2004)48, authors established that the percutaneous technique offers 
shorter operative times and lower risk of infection, but they were unable to definitively 
identify the most effective surgical tendon repair technique.
2.3.4 Non-operative treatment
Complications such as wound infection or anesthetic complications have been the 
primary reason behind continued focus on the non-operative versus operative 
management of acute Achilles tendon rupture. Traditional non-operative treatment of 
acute Achilles tendon ruptures with immobilized casting of the extremity for eight weeks 
has been challenged due to functional complications such as muscle atrophy, decreased 
ankle range of motion, and loss of coordination and proprioception1111. Removable 
bracing with a refined rehabilitation protocol has been effective in non-operative 
treatment™'l<)6' 110 ll2. The use of a heel lift in the initial stages of healing to maintain a 
position of 45° to 30° plantar flexion has also been supported in the literature47 7K. The 
amount of time spent immobilized after an Achilles tendon rupture has not been 
definitively determined in the literature, ranging from as soon as tolerated to four 
weeks86' 106' n0’61.
Karkhanis et al (2010)47 completed a retrospective study to establish the outcome of non­
operative care of the Achilles tendon rupture using a removable walker boot. A non- 
compressible felt covered polystyrene wedge of 1 cm was placed in each boot, which
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allowed 30° to 40° plantar flexion. Patient was allowed to mobilize full weight bearing as 
pain would allow, initially with the help of crutches. Of the 107 patients, 98% (105/107) 
reported clinical healing (no tenderness at rupture site and no palpable gap). Average 
time to return to work/sports/pre-injury level of activity was seven months (3 days to 48 
months). The Achilles tendon rupture score (ATRS) was completed by 56 patients via 
postal correspondence, and resulted in an average of 21 out of a possible 100 (10 
questions of 10 points each), where one was no limitation and 10 was complete 
limitation. 77% of these patients had returned to their pre-injury level of activity. 73% 
(41/56) were completely satisfied with their treatment, while 21% (12/56) were 
moderately satisfied and three were not satisfied with the treatment. Authors concluded 
that their protocol in functional treatment through early mobilization of non-operative 
care for Achilles tendon ruptures remains a viable and successful option.
2.3.5 Operative versus Non-operative treatment: A review of the 
literature
There is a great amount of literature on the comparison between operative and non­
operative care of acute Achilles tendon rupture. The following are a few of these studies 
comparing the differences in results in outcome of the two treatments with varying 
methods in rehabilitation protocol.
Nistor et al (1981 )so completed a prospective randomized study of 105 patients to 
compare the outcomes of operative versus non-operative treatment of the acute Achilles 
tendon rupture. The operative group was fitted with a below-the-knee plaster cast for six 
to nine weeks following surgery. During the first two to three weeks the ankle was
maintained in a position of slight plantar flexion. The non-operative group was 
immobilized in a below-the-knee plaster cast in gravity plantar flexion for four weeks. 
The equinus angulation was then gently reduced and another plaster cast was applied. 
Immediate full-weight bearing was permitted. A 2.5cm heel-lift was placed in the shoe 
for four weeks or until the patient was able to dorsi flex greater than 10°. Outcomes 
measured included ankle range of motion, calf circumference, tendon width, plantar 
flexion strength, ability to walk, ability to stand on tiptoe, time from work and re-rupture 
rate. There were two re-ruptures in the operative group and five in the non-operative 
group (p = 0.44). There were two major primary complications which were deep wound 
infections. There were also 29 secondary complications in the operative group. The non­
operative group (mean = 9 weeks) had significantly less time away from work (p < 0.05) 
than the operative group (mean = 13 weeks). There were statistically significantly more 
patient-reported difficulties with shoes due to tendon broadening, and stiffness in the 
ankle joint (p < 0.05) in the operative group. No other significant differences were noted 
in the study.
Cetti et al (1993) completed a randomized study comparing operative (n = 56) versus 
non-operative (55) treatment of Achilles tendon rupture. Patients in both groups were 
immobilized in a below knee cast for four to six weeks. Outcomes included ankle range 
of motion, calf circumference, subjective reports of pain, discomfort, stiffness, problems 
with shoes, time off work, and resumption of sport activities, ability to stand on tiptoe, 
walk, and run. There were three re-ruptures in the operative group and seven in the non­
operative group (p = 0.19). The operative group had two deep wound infections and the 
non-operative had one extreme residual lengthening of the tendon. The operative group
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showed statistically significantly better ankle range of motion (p = 0.002), and less calf 
atrophy (p = 0.017). Minor complications were statically significantly less in the non­
operative group (p = 0.004). The operative group had statistically significantly better 
results for time taken to resume sport at the same level as before (0.005).
In 1997, Lo et al5‘s published results of a quantitative review comparing the treatment of 
operative versus non-operative treatment of acute Achilles tendon ruptures. They 
included 19 studies in their review. The overall re-rupture rate was 2.8% for the operative 
studies and 1 1.7% for the non-operative studies (p < 0.01). The rate of minor and 
moderate complications in operatively treated patients was 20 times that of non-operative 
(p < 0.01). Authors were not able to conclusively recommend the optimal treatment for 
an acute Achilles tendon rupture.
Moller et al (2001 )7<s published results of a prospective, randomized study comparing 
operative (n = 59) and non-operative (n = 53) treatment of acute achilles tendon rupture. 
Operative care was followed by early functional rehabilitation and non-operative care 
was treated with plaster splintage for eight weeks. Outcomes measured included ankle 
range of motion and calf circumference. Time to return to work was recorded, and time 
taken to resume sports and patient opinion of treatment were recorded using the Mantel- 
Haentzel test. A visual analogue scale (VAS) was also used to evaluate the patient’s 
opinion of their treatment and a functional performance was measured using a functional 
index for the lower leg and ankle (FIL). Re-rupture after non-operative care was 11 
(20.8%) compared with one patient (1.7%) after operative treatment (p < 0.01). The 
operative group had statistically significant greater improved reported VAS quality of life 
scores (p < 0.01) at eight weeks, six months, one year and two years post injury. The
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operative group also had statieally significantly less taken to return to work than the non­
operative group (p = 0.06). There were 10 complications due to operative care, but none 
resulted in permanent functional impairment. There were no other significant differences 
in groups.
In 2002, Bhandari et alx published results of a systematic overview and meta-analysis of 
treatment for acute Achilles tendon ruptures. They compared the results of randomized 
and quasi-randomized trials to determine the effect of surgical versus conservative 
treatment. Their primary outcome was re-rupture rate, and secondary outcomes included 
deep infection rates, return to normal function, and minor complaints. Six studies met 
eligibility criteria and three investigators independently graded study quality and 
abstracted relevant information. Surgical repair significantly reduced the risk of re­
rupture when compared with conservative treatment (3.1% versus 13%; RR = 0.32; 95% 
Cl 0.14 to 0.71, p < 0.01). Five studies included information on infection rates (n = 421). 
Infections occurred only in the surgically treated patients (4.7%). The relative risk (RR) 
of infection with surgical repair was 4.6 times greater than in the cast treatment (95% Cl 
1.2 to 17.8, p = 0.03). There was no significant difference in return to normal function 
and spontaneous complaints found in the pooled analysis of five studies (n = 421). 
Authors concluded that operative treatment significantly reduces the risk of re-rupture, 
but increases the risk of complications when compare to non-operative treatment of 
Achilles tendon rupture.
Weber et al (2003)'1(1 completed a retrospective cohort study to describe a new non­
operative protocol for Achilles tendon rupture and compare outcomes to operative 







simple tendon suture and rehabilitated in a removable ankle-foot orthosis in neutral ankle 
position and with full weight bearing as soon as tolerated. The authors consecutively 
treated the prospective non-operative group (n = 23) with a slightly modified 
rehabilitation protocol in an equinus ankle casting of semi-rigid tape and a removable 
boot with a three centimeter wedge. The tape was removed after seven days. The patients 
continued rehabilitation in a removable boot with a heel lift and were permitted full 
weight bearing as soon as tolerated. Outcomes measured included ankle range of motion, 
tendon length, isokinetic strength, single-leg heel raises, and a modified Thermann score 
was used to record subjective and objective parameters. There was a significantly shorter 
period of pain at rest (p = 0.01), a shorter period of walking with crutches (p < 0.01), and 
less absence from work for the office workers (p = 0.01) in the non-operative group. All 
of the other parameters showed no statistically significant differences between the 
groups.
Twaddle et al (2007)106 completed a randomized, controlled trial in which they 
hypothesized that there was no difference in the outcome of acute Achilles tendon rupture 
treated operatively (n = 20) and non-operatively (n = 22). Following surgery, operative 
patients were placed in a position of plantar flexion in a plaster of Paris cast for 10 days. 
Both groups then received the same rehabilitation instructions. All patients remained non­
weight bearing on crutches for six weeks. After 10 days, the cast was removed and a 
below-the-knee orthosis with 20° plantar flexion was fitted. Patients were allowed to 
complete instructed range of motion exercises with removal of the orthosis for five 
minutes every hour. At four weeks the orthosis was brought to neutral, and at six weeks 
patients were allowed to bear weight as tolerated with crutches in the orthosis. At eight
weeks the orthosis was removed and patients were instructed to wean themselves from 
the crutches. Outcome measures included calf circumference, ankle range of motion.
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squeeze test reactivity, and the musculoskeletal functional assessment index (MFAI) 
validated outcome score. There were two re-ruptures in the operative group and one in 
the non-operative group. Authors found no significant differences in any of their 
outcomes as they hypothesized.
Metz et al (2008)72 completed a randomized controlled trial to compare minimally 
invasive surgery (n = 42) with non-operative treatment (n = 41) of the Achilles tendon 
with immediate full weight bearing. They hypothesized that non-operative treatment with 
removable orthosis as functional bracing would reduce the number of complications 
compared to surgery. The operative patients were placed in a cast with the foot in plantar 
flexion for one week. In the following six weeks, tape bandage was applied, supported by 
a two centimeter heel raise the first two weeks; thereafter, the height was reduced to 1cm. 
During the last two weeks, the heel raise was removed. Non-operative therapy consisted 
of a cast in plantar flexion for one week; thereafter, a functional bracing system was 
applied. In the first two weeks, the brace was fixed in 30° of plantar flexion. In the 
following two weeks, bracing was in 13° of plantar flexion. In the last two weeks, the 
brace was applied in a dynamic status enabling movement from neutral position to 30° of 
plantar flexion. Primary outcome was the number of complications other than re-ruptures. 
Secondary outcomes included time to resume work, sport participation, patient 
satisfaction of treatment and pain measured with a visual analogue scale, and Leppilahti 
scores which include subjective, objective assessment and isokinetic strength. There were 
five re-ruptures in the non-operative group and three in the operative group (p = 0.44).
For both groups crutches were advised in the first week of casting, thereafter it was left to 
the discretion of the physician and weight bearing as tolerated. The total number of 
complications on the intention-to-treat basis was 12 of 42 (29%) for surgical treatment 
and 20 of 41 (49%) for non-operative treatment. The total number of complications other 
than re-rupture on the inlention-to-treat basis was 9 of 42 (21%) for surgical treatment 
and 15 of 41 (36%) for non-operative treatment. The operative group (59 days, ± 82) had 
significantly less days off work compared to the non-operative group ( 108 days, ±115) 
(difference 49 days, 95% Cl 4 to 94, p < 0.05). Authors did not find a significant 
statistical difference in complication rates between groups as hypothesized.
A review by Khan et al (2004)4X evaluated the relative effects of surgical versus non- 
surgical treatment, or different surgical methods for acute Achilles tendon ruptures in 
adults. They included 12 trials with 844 participants. Open surgical treatment compared 
with non-surgical treatment was associated with a statistically significant lower risk of re­
rupture (risk ratio = 0.41, 95% Cl 0.21 to 0.77, p < 0.01), but a higher risk of other 
complications including infection (RR = 4.89, 95% Cl 1.09 to 21.91 p = 0.04), adhesions 
and disturbed skin sensibility (numbness). Open surgical repair was associated with a 
higher risk of infection (RR = 9.32, 95% CI 1.77 to 49.16) compared to percutaneous 
repair, however, the studies contained low numbers of participants.
Willits et al (2010)'12 completed a randomized trial comparing operative versus non­
operative care of Achilles tendon rupture with accelerated functional rehabilitation. This 
study supplied results for our retrospective cohort control group in our comparison of the 
use of autologous conditioned plasma (ACP) in non-operative treatment of Achilles 




one of the two treatment groups. All patients received a removable below-the-knee 
orthosis with a two centimeter heel lift to provide approximately 20° of plantar flexion. 
Patients were given crutches and told not to bear weight on the leg. At two weeks patients 
were allowed to weight bear with crutches as tolerated and physiotherapy protocol began. 
At six weeks the heel lift was removed and independent weight bearing as tolerated was 
encouraged. The primary outcome was re-rupture rate. Secondary outcomes included 
isokinetic strength, the Leppilahti score, range of motion, and calf circumference. There 
were two re-ruptures in the operative group and three in the non-operative group. There 
was a small but significant difference in the plantar flexion strength ratio (affected to 
unaffected limb) at 2407s at one year (mean difference, 20.25%; 95% Cl, 0.07% to 
40.4%; p = 0.05) and two years (mean difference, 14.15%; 95% Cl, 1.12% to 27.19%; p 
= 0.03) in favor of the operative group. The side-to-side difference in plantar flexion 
range of motion was greater in the non-operative group than in the operative group (mean 
difference between groups, -2.21 °; 95% Cl, -3.9° to -0.5°; p = 0.01) at two years. The 
authors found no definitive difference in the effectiveness of operative versus non­
operative treatment specifically with the use of accelerated functional rehabilitation.
In this same study by Willits et al (2010)'l2, the authors completed a systematic review of 
the literature. They pooled data from ten studies that compared operative versus non­
operative treatment of Achilles tendon rupture. They further separated the studies into 
those with rehabilitation with immobilization and limited weight bearing versus those 
with early mobilization and weight bearing. They found lower re-rupture rates in studies 
with early mobilization compared to those with immobilization as the primary 
rehabilitation approach, for operative and non-operative groups.
Summary: Of the studies we reviewed, those with significantly greater re-rupture rates 
in the non-operative groups had patients immobilized in a cast for four to eight weeks as 
part of their rehabilitation protocols. There appears to be no significant difference in re­
rupture rates between operative and non-operative treatment for acute Achilles tendon 
ruptures with accelerated functional rehabilitation protocols. Operative treatment 
however, results in significantly greater complication rates than non-operative treatment.
2.4 Immobilization versus Early Mobilization
The optimal post-operative or conservative treatment rehabilitation protocol for Achilles 
tendon rupture remains controversial . Early mobilization, as soon as three days post­
operative, has been shown to be beneficial in studies done on rats4'. Other studies 
confirmed that application of tension at the early stages of healing speeds up realignment 
of collagen fibers, increases tensile strength and minimizes deformation at the repair 
site30' 35' H5. Traditional rehabilitation protocols have suggested six to eight weeks of 
below knee cast immobilization. There is however a growing trend in the literature to 
establish the benefits of early mobilization, with the recent success in studies which have 
shown early mobilization to be more effective72' I03' 106‘lia 112.
Cetti et al (1994)14 completed a prospective randomized trial of patients (n = 60) with 
operative treatment of Achilles tendon rupture by comparing patients using a new mobile 
cast and early weight bearing (n = 30) with those using a below the knee cast (n = 30). 
Outcomes included interviews where patients were asked questions about their 
discomfort with the cast or mobile cast, pain, stiffness, time to work and sports activities, 
shoe problems, ability to walk, and ability to stand on tiptoe. Measured outcomes
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included calf circumference, ankle range of motion, plantar flexion strength, and 
radiographic evaluation of the tendon. Sixty percent (18/60) of patients in the rigid cast 
group had discomfort with their cast, and 30% (9/60) had discomfort from the mobile 
cast (p < 0.01). Immediately after removal of the cast, the mobile cast group showed 
greater mean range of motion (54.3° versus 29.5°) (p < 0.01). Twenty-three patients 
(77%) thought that the mobile cast was excellent while six patients (20%) thought that 
the rigid cast was excellent (p < 0.01). Patients in the rigid cast group showed 
significantly greater atrophy (p < 0.01) than the rigid cast group. At three months the 
mobile cast group showed statistically significant improved results in gait (p < 0.02), 
ability to stand on toes (p < 0.03), ankle range of motion compared with contra-lateral 
side (p < 0.01), normal ankle range of motion which was defined as 40°-70° plantar 
flexion and 15°-30° dorsi flexion (p < 0.02), and general complaints (p < 0.05). At six 
months there were statistically significant improvements of the mobile cast group for 
ability to stand on toes (p = 0.01), ankle range of motion compared to contra-lateral side 
(p < 0.01), and normal ankle range of motion (p < 0.02). At one year post-operative the 
mobile cast showed significantly greater improvements in ankle range of motion 
compared to the contra-lateral side (p < 0.01), normal ankle range of motion (p < 0.02), 
and complaints (p = 0.03). At one year the mobile cast group also had significantly less 
atrophy than the rigid cast group (p < 0.02). The mobile cast group showed significantly 
greater calf strength at three months, six months and one year (p < 0.01). At one year 
there were significantly more patients who returned to their same level of activities in the 
mobile cast group (p < 0.03). There was one re-rupture in the mobile cast group and two
re-ruptures and one infection in the rigid cast group. This study showed favorable results 
of early mobilization for patients after operative treatment of Achilles tendon rupture.
McComis et al (1997)70 completed a pilot investigation in the use of a functional bracing 
protocol for patients with Achilles tendon rupture who were treated non-operatively. 
Fifteen patients were included in the study and followed for a mean period of 31 months. 
A control group of patients from the local community were matched on age and gender to 
provide normative data for the comparison of side-to-side differences. Outcomes 
included a subjective questionnaire (pain, weakness, limp, sensitivity to change in 
weather), range of motion, calf circumference, results of the Thompson squeeze test, and 
a single-limb heel-rise test. In addition, ground-reaction forces and temporal data were 
assessed during functional dynamic activities that included walking, a single-limb power 
hop, and a 30 second single-limb heel-rise endurance test. The study group had a mean of 
2.6° greater dorsi flexion than the control group (p = 0.02). There was a weak but 
significant relationship between passive dorsi flexion of the ankle and vertical force 
output during gait (r = 0.40, p = 0.05); specifically, the magnitude of the difference in 
vertical force output between the mid-stance and terminal-stance phases of gait increased 
as the range of dorsi flexion increased. Authors concluded that their results showed non­
operative functional bracing with a below knee cast to be a viable option for treatment of 
Achilles tendon rupture as there were no clinically important differences found between 
their study group and the matched control group. However, the low number of 
individuals in the study is a limitation of the results.
Mortenson et al (1999)77 completed a prospective, randomized, controlled trial to 











motion of the ankle in a below-the-knee brace for six weeks (n = 31), in acute operative 
I care of Achilles tendon rupture. Outcomes included calf circumference, ankle range of
motion, interviews concerning pain, stiffness, tenderness, ability to walk and run, number 
of work days missed, return to sport, tiptoe standing, tendon thickness, heel raise, 
isometric strength, and subjective opinion on progress and treatment. The early motion 
group took significantly fewer sick days (p < 0.05) and reported greater satisfactory 
subjective results (p < 0.05) than the cast group. The early motion group also reported 
I earlier time to resume sports (p < 0.01) and time until pre-injury participation level was
reached (p < 0.01). The early motion group also had significantly fewer adhesion 
complications (p < 0.01). At the time that the brace and cast was removed, the early 
I motion group had significantly less restricted range of motion (range being 0°-45° from
full dorsi to full plantar flexion) (p < 0.01), and there was still a significant difference at 
12 weeks (p < 0.05). There was one re-rupture in the early motion group and two in the 
cast group. This study showed favorable results for early motion protocol in the operative 
treatment of Achilles tendon rupture, however, their follow up was only up till 12 weeks 
and then one more follow up time with a median of 16 months.
Moller et al (2001 )76 prospectively randomized 112 patients with acute Achilles tendon 
rupture, into an operative group (n = 59) with early functional rehabilitation using a 
brace, and a non-operative group (n = 53) with plaster splintage for eight weeks. The 
non-operative group wore a below-knee plaster cast with the ankle in equinus for four 
weeks. The cast was then changed to the ankle in a neutral position. This was worn for a 
further four weeks and weight-bearing allowed. The foot was placed in a below-knee 




bearing and range of motion exercises were encouraged during weeks three through 
eight. The brace initially prevented dorsi flexion beyond 30° of equinus. Movement to 
10° of equinus was allowed at four weeks and after six weeks dorsiflexion of 10° was 
permitted. A bilateral heel-raise of 15 mm for four to eight weeks and identical 
rehabilitation protocols were used in both groups. Full weight-bearing without crutches 
was allowed at eight weeks. Outcomes included calf circumference, ankle range of 
motion, times to resume work and sports participation, a visual analogue scale (VAS) for 
patient opinion of their treatment, functional index for the lower leg and ankle (FIL) to 
measure functional performance, isokinetic ankle strength, and a heel raise test, There 
was one re-rupture (1.7%) in the operative group and 11 in the non-operative group 
(20.8%) (p < 0.01). There were 12 cases of complications in the operative group. There 
was a significant difference in patient-reported visual analogue scale (VAS) for quality of 
life at eight weeks (p < 0.01), as well as six months (p < 0.01), one year (p < 0.02), and 
two years (p < 0.01). The time before return to work in the operative group was 54.9 days 
(0 to 197) compared with 73.4 days (0 to 250) in the non-operative group (p = 0.06). 
Authors concluded that there were no significant differences in functional outcomes, but 
the high re-rupture rate in the non-operative group was significant.
Maffulli et al (2()03)fl1 completed a comparative longitudinal study of early weight 
bearing versus immobilization of the surgically repaired acute Achilles tendon. Patients 
in group I (n = 28) underwent immobilization with the ankle in physiological equinus for 
two weeks, and in neutral for four weeks. These patients were encouraged to weight bear 
on the limb as soon as tolerated. Patients in group II underwent immobilization for two 




equinus. Patients were advised to weight bear at this point with the ankle in neutral. 
Outcome measures included calf circumference; isometric gastro-soleus strength; high 
resolution real time ultrasound assessment (HRRTUS); and a questionnaire detailing 
satisfaction, effect on occupational and sporting activities, and pain. Group I also 
completed and additional 4-point scale which accounted for pain, difficulty in 
recreational and activities of daily living, footwear restrictions, and patient satisfaction in 
relation to outcome of surgery. Patients in group 1 discarded their crutches significantly 
earlier (p = 0.013). Number of outpatient visits were significantly less in group I (p = 
0.025), and group I patients also attended significantly less physiotherapy sessions and 
were discharged earlier from therapy (p = 0.008). Average time for group 1 to return to 
sport was also marginally significantly less (p = 0.046). The authors concluded that there 
was no adverse effect to early weight bearing following open repair of the ruptured 
Achilles tendon.
Costa et al (2006)20 completed two independent randomized control trials to assess the 
potential benefits of immediate weight-bearing mobilization after rupture of the Achilles 
tendon. In the first trial, 48 patients consented to enter the trial with operative treatment 
of their injury (n = 23 in early mobilization group, n = 25 in control group). In the second 
trial, 48 patients consented to enter the trial with non-operative treatment of their injury 
(n = 22 in early mobilization group, n = 26 in control group). The operative repair trial 
received simple, open end-to-end repair, with the exception of two patients who were 
found to have complex ruptures at operation. These patients received augmented repairs, 
with a tendon lengthening procedure and bone anchors respectively. Both were followed 
up on an intention-to-treat basis within their allocated treatment group. For all subjects in
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the operative trial, the limb was placed in a temporary gravity equinus plaster overnight. 
Immediate mobilization in a carbon fiber orthosis with three 1.5cm heel raises were used 
for the treatment group and traditional plaster cast immobilization was used in the control 
group. Patients were seen every two weeks for an eight week period during which the 
equinus position of the plaster or the number of heel raises in the orthosis was reduced. 
The plaster cast or orthosis was removed at eight weeks.
Patients in the second trial treated non-operatively, followed the same protocol as the 
first for the early mobilization and control groups respectively, with the exception of the 
removal of the cast or orthosis at 12 weeks instead of eight. Patients in the treatment 
group were also mobilized with full weight-bearing and encouraged to move the ankle 
within the orthosis. In the second trial patients were not offered formal physiotherapy. 
The primary outcome was patient-reported time taken to return to normal activity. Return 
to normal sport activity, walking, stair climbing, and work activity were also recorded. In 
addition, the EuroQol health status questionnaire was completed, as well as calf strength. 
Five patients were lost to follow-up in both trials. There was a significant difference in 
the first (operative) trial for return to walking (p = 0.03) with a median of 12.5 weeks in 
the treatment group and 18 weeks in the control group. There was also a significant 
reduction in the time taken to return to normal stair climbing (p = 0.02) with a median of 
13 weeks in the treatment group and 22 weeks in the control group. There were two re­
ruptures in the treatment group, one due to slipping on ice while in the orthosis, the other 
breaching protocol and running on a treadmill too soon after removal of the orthosis. 
There were six minor wound complications in the treatment group and five in the control 
group. There were no significant differences in any of the outcomes for the second (non­
operative) trial. There was one re-rupture in the treatment group, and one re-rupture and 
two other major complications in the control group. The authors conclude that the first 
trial provides further evidence of an improved functional outcome for patients mobilized 
fully weight-bearing after operative repair. The second trial did not provide evidence of a 
functional benefit of immediate weight-bearing mobilization; however, the practical 
advantages of early weight bearing did not predispose these patients to a higher 
complication rate.
Majewski et al (2008)6< completed a comparative study on post-operative management 
following percutaneous repair of acute Achilles tendon rupture. One hundred and three 
patients were prospectively entered into their database. Before July 1999, 15 patients 
were treated post-operatively with below-knee cast immobilization in 20° plantar flexion 
with complete non-weight bearing for three weeks. This was followed by five weeks of a 
below-knee walking cast with crutches. After eight weeks the cast was removed and the 
patient was allowed to weight-bear during physical therapy, and gradually during daily 
activities with appropriate shoes until 12 weeks. After July 1999, patients wore a splint 
that held the foot in 20° plantar flexion for the first day, and after that a special shoe with 
a 3cm wedge was worn during the day and the splint at night. After four weeks the 
threecm wedge was reduced by one cm each week, and partial weight-bearing exercises 
with bare feet were started. Patients were allowed to be full-weight bearing with crutches 
as tolerated in the shoe from the beginning of the protocol. Patients were seen at 6 weeks, 
12 weeks, and 12 months after surgery. Matched pairs were selected based upon gender, 
age, weight, height, body mass index, and the side involved. The total number of patients 
consisted of 14 matched pairs. Outcomes included range of motion, endurance (heel
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raises), return to work and sports activity, subjective outcome, Achilles tendon scores 
(Hannover Achilles tendon score). For an objective endurance test, nine patients in the 
cast group showed a reduction of up to 35% and 6 patients from the shoe group showed a 
reduction of up to 15%. The patients immobilized in a cast (mean = 67) had significantly 
(p = 0.04) longer periods away from work compared to the patients treated with early 
functional therapy (mean = 37). Authors found a significant (p < 0.04) difference in 
levels of restriction in sports, as compared with the level of play prior to injury in favor of 
the shoe group. Patients immobilized in a cast rated their outcome significantly (p < 0.05) 
less satisfying compared to the patients treated with early functional therapy. Authors 
concluded that their results showed early functional therapy with mobilization and full 
weight bearing in a specially designed shoe provides a better clinical outcome and 
enables earlier return to work and sports activities after surgery.
Suchak et al (2005)w completed a randomized study to compare the effect of early 
weight-bearing with that of non-weight bearing on early post-operative recovery 
following repair of an acute Achilles tendon rupture. One hundred and ten patients were 
enrolled in the study and all were non-weight bearing for the first two weeks following 
surgery in a posterior splint with the ankle in a relaxed equinus position. After two weeks 
the posterior splint was removed and the patients were managed with a fixed-angle 
hinged ankle-foot-orthosis set at the position of rest (~ 20° of plantar flexion). Patients in 
both groups were instructed to gradually bring the fixed-angle hinge to 0° of plantar 
flexion over the first two to three weeks. The patients were given an instruction sheet 
detailing boot adjustments over two to four-day periods and what symptoms to monitor to 







dorsiflexion range- of-motion exercises. Twice daily, patients removed the ankle-foot- 
orthosis and performed these range-of-motion exercises as tolerated. Patients were 
randomized to either weight bearing as tolerated or non-weight bearing with crutches for 
an additional four weeks. Compliance was measured with a pressure sensor in the fixed- 
hinge ankle-foot orthosis. At six weeks patients were allowed to wean themselves from 
the orthosis as tolerated. The primary outcome was the six-week postoperative health- 
related quality-of-life score with use of the RAND-36 questionnaire. Strength, range of 
motion, calf circumference, single-leg heel-raises, and patient reported activities of daily 
living/work/sport were also documented pre- and post-operatively. There were 
significantly greater scores on the RAND-36 questionnaire for the weight-bearing group 
(physical functioning p = 0.03, social functioning p = 0.03, vitality p = 0.04, role- 
emotional 0.02) at six weeks. Also at six weeks, 43% of the weight-bearing group and 
9% of the non-weight bearing group reported either no limitations or limitations only 
with recreational activity (p < 0.01). The results of this study showed evidence of a 
benefit to weight-bearing as tolerated following operative care of Achilles tendon rupture.
Summary: Several studies support early mobilization for the operative or non-operative 
treatment of Achilles tendon rupture. Early motion results in fewer functional 
complications than immobilization and has shown reduced re-rupture rates for non­
operative care of Achilles tendon rupture.
2.5 Platelet-rich Plasma
Platelet-rich plasma (PRP) is an autologous concentration of human platelets in a small 








autologous blood having a platelet concentration above baseline07. Platelet-rich plasma 
(PRP) has also been referred to as, autologous conditioned plasma (ACP®), platelet 
enriched plasma (PeRP), platelet-rich concentrate (PRC), autogenous platelet gel, or 
platelet releasate, dependant on the commercial preparation system used, the platelet 
concentration, or the anticoagulant or activator used“ . The most commonly used term 
in the literature is platelet-rich plasma (PRP). For this reason (and for simplicity) we will 
use PRP to mean any of these other terms throughout this review of the literature.
[ 2.5.1 Histology
Platelets are cytoplasmic fragments of megakarocytes, a type of white blood cell, and are 
formed in the marrow2' 90. They are the smallest of the blood cells, round or oval in shape 
and approximately two pm in diameter. They lack nuclei but contain organelles and 
structures such as mitochondria, microtubules, and granules (a, 5, >.) . Platelets contain 
more than 30 bioactive proteins, many of which have a fundamental role in haemostasis 
or tissue healing2.
Cells are able to initiate tissue repair by proliferation, a phase that involves either local 
cells or undifferentiated cells migrating to the injured area through blood flow45. Since 
platelets are renowned as the major sources of healing factors within blood clots, the idea 
that concentrating them at the injured site could somewhat accelerate and optimize the 
healing mechanisms set the rationale for the development of PRP89. PRP used in human 
models is always autologous (patient obtained) and is not homologous (donor obtained)07.
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2.5.2 History in the use of PRP
Since the 1990’s, PRP has been used successfully in an array of fields of study including 
maxilla-facial surgery6S and plastic surgery64. A growing body of laboratory evidence 
supports the use of PRP injections for the treatment of muscle and tendon injuries and 
degeneration7 l<IK. Its use in sports medicine is growing given its potential to enhance 
muscle and tendon healing. In vitro and in vivo studies suggest that growth factors 
released by platelets recruit reparative cells and may augment soft-tissue repair56' 56.
2.5.3 The effect of PRP on tissue
Marx et al (2004)67 effectively described the working mechanism of PRP in relation to 
tissue and cells: ‘PRP works via the degranulation of a granules in platelets, which 
contain the synthesized and prepackaged growth factors. The active secretion of these 
growth factors is initiated by the clotting process of blood and begins within 10 minutes 
after clotting. As the clotting process activates the platelets, the growth factors are 
secreted from the cell through the cell membrane. In this process, the a granules fuse to 
the platelet cell membrane where the protein growth factor is completed to a bioactive 
state by the addition of histones and carbohydrate side chains to these proteins. The 
secreted growth factors immediately bind to the external surface of cell membranes of 
cells in the graft, flap, or wound via transmembrane receptors. These transmembrane 
receptors in turn induce an activation of an endogenous internal signal protein, which 
causes the expression of (unlocks) a normal gene sequence of the cell such as cellular 
proliferation, matrix formation, osteoid production, collagen synthesis, etc. The 
importance of this knowledge is that the PRP growth factors never enter the cell or its
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nucleus, they are not mutagenic, and they act through the stimulation of normal healing, 
just potentially much faster. After the initial burst of PRP-related growth factors, the 
platelets synthesize and secrete additional growth factors for the remaining seven days of 
their life span. Once the platelet is exhausted and dies off, the macrophage, which has 
arrived in the region via the vascular in-growth stimulated by the platelets, assumes the 
function of wound healing regulation by secreting some of the same growth factors as 
well as others.’
Essentially, PRP acts on healing capable cells via local secretion of growth factors to 
increase their numbers (mitogenesis) and stimulate vascular ingrowth (angiogenesis)27"s2,
6S. Another advantage of the use of platelet-rich therapies is the antibactericidal effects of 
the antibacterial and fungicidal proteins stored in platelets, which may help to prevent 
infection9 The effect of PRP on tissue healing is a function of many variables, 
including platelet concentration, the volume of PRP delivered, the extent and type of 
injury, and the overall medical condition of the patient2. Debate continues regarding the 
optimal quantity of platelets and growth factors required for muscle and tendon healing . 
A platelet concentration of 1, 407, 640pl (SD 320, 100 or 10% of the PRP volume) has 
been suggested to be the working definition of PRP1 " .A  concentration four or more 
times that of whole blood has also been proposed67, but lower concentrations of two to 








2.5.4 Growth factors present in PRP and their roles
Because it is a concentration of platelets. PRP is also a concentration of the eight 
fundamental protein growth factors proved to be actively secreted by platelets to initiate 
all wound healing. Table 1 includes these growth factors and their functions2. Because 
these concentrated platelets are suspended in a small volume of plasma, PRP is more than 
just a platelet concentrate; it also contains the three proteins in blood known to act as cell 
adhesion molecules for osteoconduction and as a matrix for bone, connective tissue, and 
epithelial migration67. These cell adhesion molecules are fibrin itself, fibronectin, and 
vitronectin67.
Table 1 Growth factors and their function
Growth Factor Function
Platelet derived growth factor (PDGF) Macrophage activation and angiogenesis
Fibroblast chemotaxis and proliferative 
activity
Enhances collagen synthesis 
Enhances the proliferation of bone cells
Vascular endothelial growth factor (VEGF) Angiogenesis
Migration and mitosis of endothelial cells
Creation of blood vessel lumen
Creates fenestrations
Chemotactic for macrophages and 
granulocytes








Transforming growth factor beta-1 (TGF-
Pi)
Enhances the proliferative activity of 
fibroblasts
Stimulates biosynthesis of type I collagen 
and fibronectin
Induces deposition of bone matrix
Inhibits osteoclast formation and bone 
resorption
Epidermal growth factor (EGF) Cellular proliferation 
Differentiation of epithelial cells
Platelet factor-4 (PF-4) Stimulates the initial influx of neutrophils 
into wounds
A chemoattractant for fibroblasts 
A potent antiheparin agent
Insulin-like growth factor-1 (IGF-1) Chemotactic for fibroblasts and stimulates 
protein synthesis
Enhances bone formation by proliferation 
and differentiation of osteoblasts
Platelet derived endothelial growth factor Promotes wound healing by stimulating the 
proliferation of kératinocytes and dermal
fibroblasts
Platelet derived angiogenesis factor 
(PDAF)
Induces vascularisation by stimulating 
vascular endothelial cells
2.5.5 Preparation of PRP
Hall et al (2009)37 describes the preparation of PRP as taking a sample of autologous, 
anticoagulated blood and using a centrifuge or filter to separate red blood cells from 
leukocytes and platelets. Plasma is divided into platelet-poor and platelet-rich portions.
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The efficiency of red blood cell separation and platelet concentration is dependent on the 
preparation system, but all PRP preparations contain the noncellular components of 
plasma, including clotting factors.
Alsousou et al (2009)2 suggest three techniques for preparation which includes: the 
gravitational platelet sequestration (GPS) technique, standard cell separators, and 
autologous selective filtration technology (plateletpheresis). The GPS is a table-top 
centrifuge system, whereby the anticoagualted blood is centrifuged and results in three 
layers of red blood cells, white blood cells, and plasma from bottom to top respectively, 
within a plastic tube. With this device, the red blood cells cannot be collected separately 
and are therefore discarded. A full unit of blood is generally necessary to operate the 
standard cell separators and salvage devices. In general they use a continuous-flow 
centrifuge bowl or a continuous-flow disk separation technique and both a hard (fast) and 
a soft (slow) spin, yielding platelet concentrations from two to four times baseline17. The 
red blood cells and all or some of the platelet-poor plasma (PPP) can be returned to the 
patient to maintain circulating volume11'. Selective filtration technology or 
plateletpheresis depends on a single-use disposable proprietary filter designed to 
concentrate platelets from whole blood. The platelets are captured on the filter and are 
then harvested to provide a platelet-rich concentrate (PRC) without the need for 
centrifugation. Compared to a commercial centrifuge-based method, the filtration device 
produces a blood fraction similarly enriched in platelets and growth factors93.
Preparation systems are distinguished by differences such as volume of autologous blood 
used, centrifuge rate/time, delivery method, activating agent, leukocyte concentration, 
final PRP volume, and final platelet and growth factor concentration. Given the
qualitative and quantitative differences, reported evidence for clinical effectiveness of 
PRP cannot be generalized across preparation systems. Hematological variation between 
patients (e.g. leukocyte count, platelet count) may also affect the final preparation37.
2.5.6 Delivery of PRP
PRP can be administered with or without an activating agent. Its combination with 
calcium chloride and/or thrombin immediately before injection initiates platelet 
activation, clot formation, and growth factor release at the injection site. Delivery of PRP 
without an exogenous activator is also commonly performed . Marx et al (2001) 
advises that clotting only be done at the time of use. Anticoagulants are used to maintain 
platelet viability. Marx et al (2001 )66 also suggests the two anticoagulants that support the 
metabolic needs of platelets and the viable separation of platelets in an undamaged 
manner, is anticoagulant citrate dextrose-A (ACD-A) and citrate phosphate dextrose 
(CPD), with the latter being the less effective of the two.
Leitner et al (2006)52 compared four different systems for the preparation of PRP which 
is available commercially. These systems included Vivistat PRF Preparation Kit®, PCCS 
Platelet Concentrate Collection System®, Harvest® Smart PRrP 2 APC 60 Process, and 
Fibrinet® Autologous Fibrin & Platelet System. It has been shown previously that the 
amount released depends on the preparation system used. The authors found Vivistat PRF 
Preparation Kit, PCCS Platelet Concentrate Collective System, and Harvest SmartPReP 2 
APC 60 Process all comparable in platelet yield and total amount of released PDGF-AB 







supernatant was achieved. The ability of growth factor release was equal in all four 
systems.
2.5.7 PRP studies
Animal studies have been used to show the effectiveness of PRP on tendon healing as 
tendon physiology is generally known to be comparative with that of humans. In the 
clinical setting however, results are often not as readily transferable because the physical 
structure of the animals differs greatly when compared to humans.
2.5.7.1 Animal studies
In 2006 Virchenko et alll,x compared five treatments: (1) platelet gel, containing 
thrombin-activated platelets and added calcium, (2) platelet gel supplemented with 
Hirudin in order to neutralize thrombin, (3) injectable platelet concentrate without 
thrombin, (4) thrombin (in saline), and (5) saline alone; in 50 Sprague-Dawley rats with 
transected Achilles tendons. Outcome measures included tendon sagittal and transverse 
diameters, and dynamic testing for force at failure, stiffness, and energy uptake at 10% 
droop of the curve. Compared to saline, platelet gel caused a 42% increase in force at 
failure (50 ± 3.7; 95% Cl 34 to 51, p < 0.01), a 90% increase in energy (159 ± 24; 95% 
Cl 63 to 1 18, p < 0.01), and a 61% increase in ultimate stress (8.8 ± 3.4; 95% Cl 19 to 
103, p < 0.01). Platelet gel with neutralized thrombin caused a 22% increase in force at 
failure (43 ± 2.0; 95 % Cl 16 to 28, p < 0.01), and energy and stress were less elevated. 
Injected platelet concentrate caused a 24% increase in force at failure (44 ±2.1; 95% Cl 
18 to 31, p < 0.01), and thrombin caused a 10% increase (39 ± 1.1; 95 % Cl 5 to 16, p < 






The PRP used in the preparation of the platelet gel was taken from 10 other rats. Authors 
concluded that both platelets alone and thrombin alone can improve tendon repair in rats, 
and there is an additive effect when combining them. Platelet gel showed the greatest 
improvement.
Also in 2006, Virchenko and Aspenberg107 completed a randomized trial in a rat Achilles 
tendon transection model where authors studied the effects of platelets on Achilles tendon 
regenerates in rats three, five and 14 days after transection. They used 130 Sprague 
Dawley rats. The platelet concentrate was prepared from 10 rats that were sacrificed. 
Twenty rats with unloading by Botox-induced paralysis of the calf muscles were 
randomized to receiving either the platelet or control injection. Then 20 rats were 
randomized to increased loading in activity cages or the control treatment (normal cages). 
They then repeated this experiment with addition of groups that received Botox and were 
randomized to activity cages or control. Finally, rats were randomized to platelet 
treatment or control (no treatment), and evaluated after three, five and 14 days. Outcome 
measures included sagittal and transverse diameter, and dynamic loading for failure, 
stiffness and energy uptake. At 14 days, unloading (with Botox) abolished any effect of 
the platelets and reduced the mechanical properties of the repair tissue to less than half of 
normal. Thus, some mechanical stimulation is a prerequisite for the effect of platelets at 
14 days. Without Botox, both activity (force, energy, and area (p < 0.05)) and platelets 
(force, stiffness, area (p < 0.05)) increased repair independently of each other. However, 
at 3 and 5 days, platelets improved the mechanical properties in Botox-treated rats. 






Kajikawa et al (2008)45 injected PRP containing various kinds of growth factors into the 
wounded area of the patellar tendon of rats (n = 60), and compared the effects on 
activation of circulation-derived cells and enhancement of tendon healing with a control 
group (no PRP injection) (n = 20). To follow the circulation-derived cells, they used a 
green fluorescent protein (GFP) chimeric rat expressing GFP in the circulating cells and 
bone marrow cells. At 3 days after injury in the control group, 25.3 ± 6.3% of GFP- 
positive cells were proliferating. In the PRP group, the proliferation rate was significantly 
higher than in the control group (56.0 ± 18.5%) (p < 0.05). At 7 days, proliferative 
activity decreased in both groups, however, in the PRP group, the proliferation rate was 
still significantly higher than in the control group (38.5 ± 16.3% to 17.3 ± 3.1) (p < 0.05). 
In the PRP group, the numbers of heat-shock protein (HSP47; collagen-specific 
molecular chaperone (-positive cells were significantly higher than in the control group at 
3 and 7 days after injury. At the same time, the immunoreactivity for types I and III 
collagen was higher in the PRP group than in the control group at early phase of tendon 
healing. These findings suggest that locally injected PRP is useful as an activator of 
circulation-derived cells for enhancement of the initial tendon healing process.
2.5.7.2 Human studies
In a cohort study, Mishra et al (2006)73 evaluated the use of (PRP) as a treatment in 20 
patients with chronic severe epicondylar tendinosis. Patients were initially given a 
standardized physical therapy protocol and a number of different non-operative 
treatments. Patients were randomized (3:1) to a single percutaneous injection of (PRP) or 
an injection of bupivacaine. They used sodium citrate as an anticoagulant, and after 
centrifugation it was buffered to physiological pH using 8.4% sodium bicarbonate.
Outcomes measures included a visual analogue scale (VAS) for pain, and a modified 
Mayo elbow score. Eight weeks after the treatment, the PRP patients noted 60% (80.3 to 
32.0) improvement in their visual analog pain scores versus 16% (86 to 72) improvement 
in control patients (p < 0.01). |RR = 0.48 (Cl 95% 0.37 to 0.61)]. The study had a low 
number of participants (n=20), with only fifteen in the PRP group and five in the control 
group. After the eight week period, three of the five patients in the control group dropped 
out.
Lee et al (2007)51 completed a prospective, randomized, controlled trial to compare 
intralesional autologous blood injection (n = 30) with corticosteroid injection (n = 31) in 
treatment of chronic plantar fasciitis. Outcome measures included the visual analogue 
scale (VAS) for pain, and the tenderness threshold at the plantar fascia origin using a 
pressure algometer. At six weeks (p = 0.01) and three months (p < 0.01) the 
corticosteroid group reported significantly lower pain scores on the visual analogue pain 
scale. At six weeks, three months and six months, the corticosteroid group showed 
significantly greater threshold levels (p < 0.01). However, a repeated measures test 
showed no significant difference over time which included 6 weeks, 3 months and 6 
months. Authors concluded that intralesional autologous blood injection is efficacious in 
lowering pain and tenderness in chronic plantar fasciitis, but corticosteroid is more 
superior in terms of speed and possibly extent of improvement.
In a case-control study and descriptive laboratory study, Sanchez et al (2007) evaluated 
12 athletes who underwent open suture repair of acute Achilles tendon rupture. Six of 
these received the repair in conjunction with a preparation rich in growth factors (PRGF). 













suture repair. Outcomes measured included functional outcome evaluation (time to reach 
full ankle range of motion, gentle running as determined by the physician, and to resume 
training activities), and cross-sectional area of the Achilles with ultrasound. Other 
outcomes included ankle range of motion, complications such as infection, wound 
healing defects, adhesions, sural nerve injury, and calcifications. A simplified construct 
of the Cinncinati function scale was used to define the elapsed time to return to return to 
sporting activities, normal training, and competition. The treatment group experienced 
earlier functional restoration of ankle range of motion (7 versus 11 weeks, p = 0.03) and 
earlier return to jogging (11 versus 18 weeks, p = 0.04) and training (14 versus 21 weeks, 
p < 0.01), as well as no wound problems. The PRGF group also had less Achilles tendon 
cross-sectional area after a mean of 18 months compared with control subjects (p < 0.01), 
as measured by ultrasonography. Authors found favorable results for PRGF and 
concluded that the application of autologous PRGF may present new possibilities for 
enhanced healing and functional recovery in the operative management of Achilles 
tendon rupture.
In 2008 Sanchez et alX7 reported the results of their observational retrospective cohort 
study where they compared the use of preparation rich in growth factors (PRGF) (n = 30) 
with intra-articular hyaluronan (HA) (n = 30), in patients with osteoarthritis. Treatments 
consisted of three weekly injections for both groups. Their primary outcome was the 
Western Ontario and McMaster University Osteoarthritis Index (WOMAC) taken prior to 
treatment and five weeks after treatments. By five weeks the PRGF group reported a 
33.4% improvement in pain subscale versus 10% in the HA group (p < 0.01). There were 















overall WOMAC scores (p = 0.01). Authors concluded that their study had considerable 
limitations, but they suggest that knee osteoarthritis treated with the application of 
autologous platelet-rich fibrin could present new possibilities for enhanced outcomes.
Everts et al (2008)28 published results of a randomized controlled trial that evaluated the 
use of platelet-leukocyte gel (PLG) in open subacromial decompression (OSD) surgery 
for 40 patients (treatment = 20, control = 20) with chronic impingement syndrome of the 
shoulder. At six weeks the PLG group showed significant improvement in VAS pain 
scores which were part of the American shoulder and elbow surgeons (ASES) shoulder 
assessment method (p < 0.01). Patients with PLG also used significantly less pain 
medication (p < 0.01) and scored significantly better on the shoulder index score (SIS) 
postoperatively (p < 0.01). Patients with PLG had significantly improved scores on the 
activities of daily living (ADL) questionnaire two weeks postoperatively (p < 0.05) and 
demonstrated greater range of motion improvement at two weeks (p < 0.05). Authors 
concluded that the use of PLG in OSD is very effective for regaining early shoulder 
function with better control of postoperative pain
Orrego et al (2008)83 performed a randomized controlled trial in 108 patients to 
determine if the use of platelet concentrate (PC) and bone plug (BP) accelerates healing 
in anterior cruciate ligament (ACL) reconstruction. The patients were randomized to PC 
(n = 26), BP (28), combination of PC and BP (n = 27), and a control group (n = 27). 
Maturation of the graft was evaluated at the femoral tunnel using MRI maturation criteria 
defined by a low-intensity signal, absence of osteoligamentous interface, and no widening 
of the femoral tunnel. Subjective and objective evaluations using the Lysholm and 
international knee documentation committee (IKDC) scores were performed pre­
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operatively and six months after surgery. The only significant difference was found at six 
months in the presence of low-intensity mature graft signal at the femoral tunnel in 78% 
of the BP group and in 100% of the PC group (p = 0.04), favorable to the PC group. 
Tunnel widening (negative result) was seen in 11% of the patients in the BP group versus 
41% of the patients in the control group (p = 047). Authors concluded that based on their 
results they were unable to find a strong clinical effect in favor of the use of PC BP.
In 2009 Silva and Sampaio95 completed a prospective study whereby 40 patients who 
underwent anterior cruciate ligament reconstruction with hamstring tendon graft were 
enrolled. Their objective was to see if PRP could promote tendon-bone healing. Patients 
were sequentially enrolled into four groups: (A) control, (B) PRP in femoral tunnels at 
the end of surgery, (C) PRP in femoral tunnels at the end of surgery as well as additional 
injections at two and four weeks post-surgery, and (D) PRP activated with thrombin and 
injected in the femoral tunnel at the end of surgery. Magnetic resonance imaging (MRI) 
was done on all patients three months after the surgery to evaluate the signal intensity of 
the fibrous interzone (FIZ) in the femoral tunnel. No significant differences between 
groups were found. Authors concluded that their results showed no acceleration in tendon 
healing in the use of PRP isolated or with thrombin.
Kon et al (2009)50 completed a prospective evaluation of 20 male athletes with chronic 
patellar tendinosis (mean, 20.7 months) who each received three PRP injections into the 
tendon at 15 day intervals. Patients were allowed to begin light activity after the second 
injection and were encouraged to begin strengthening activities after the third injection. 
The EQ-VAS, SF-36 Item Short Form questionnaires, and Tegner were completed by 



















adverse events, and all participants had significant improvements in EQ-VAS for all time 
point comparisons (p < 0.01); for SF 36-Item Short Form after final treatment compared 
to baseline (p < 0.01), and Tegner activity scores at the six month follow-up (p < 0.01). 
Eighty percent of participants (16/20) were satisfied with their results, and 70% (14/20) 
showed complete or marked functional recovery. Authors suggest that this method may 
be safely used for the treatment of jumper’s knee, by aiding the regeneration of tissue 
which otherwise has low healing potential.
De Vos et al (2010)24 performed a randomized controlled trial of 54 patients with chronic 
tendinopathy two to seven centimeters above the Achilles tendon insertion. Patients were 
randomized to receive a PRP injection (n = 27) or placebo (n = 27). The validatedI Victorian Institute of Sports Assessment-Achilles (VISA-A) questionnaire, which 
evaluated pain score and activity level, was completed at baseline and six, 12, and 24 
weeks. Secondary outcomes included subjective patient satisfaction, return to sports, and 
adherence of eccentric exercises. Authors found no statistically significant differences 
between treatment groups for any of their outcomes and concluded that they were unable 
to find any clinical benefit in the use of PRP in chronic mid-portion Achilles 
tendinopathy.
Summary: There are currently mixed results regarding the clinical outcomes following 
PRP preparations applied to injured tissue. Much more work is required to determine the 
role of PRP in the treatment of soft tissue healing and specifically its effectiveness in 
tendon healing after injury. As its biological benefits have been explained, the fact that it 
may reduce healing time and improve strength in the musculo-tendonous complex in 
acute Achilles tendon rupture still needs to be established. The availability of our
52
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historical cohort gave us the opportunity to explore and compare this with a prospective 
study.
3 Chapter 3: Study Objectives
3.1 Primary Objective
Our primary objective was to compare the isokinetic strength of the gastrocnemius-soleus 
complex at one year between patients with an acute Achilles tendon rupture who received 
two ACP® injections and a historical control group who received similar rehabilitation 
but no ACP® injections.
3.2 Secondary objectives
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The secondary outcomes included ankle range of motion, calf circumference, Achilles 

















4 Chapter 4: Methods
4.1 Study design
This was a prospective cohort study with historical controls. The historical controls were 
gathered from a randomized trial that compared operative versus non-operative treatment 
for Achilles tendon rupture. For the purposes of our study, we used the data from the 34 
patients who were randomized to the non-operative group of the randomized controlled 
trial (RCT) for which there was data at one year. For the prospective cohort study, we 
recruited 73 consecutive patients who were referred to our facility from emergency rooms 
in London, Ontario, Canada and surrounding areas. Criteria for referral were a complete 
Achilles tendon rupture upon examination at the emergency room with diagnosis by 
ultrasound, presence of a palpable gap21 or Thompson Squeeze test104. One of the authors 
(KW) confirmed the diagnosis at our facility within two weeks of the initial injury, and 
patients signed a letter of informed consent to participate in the study. The study was 
approved by the institutional research ethics board at the University of Western Ontario 
(Appendix 1).
The historical cohort contained results for outcome measures at one year and two years 
only. This thesis includes the analysis of outcomes at one year post-injury. The study in 
its entirety includes outcome measures at six months, one year, 18 months, and two years, 
and was ongoing at the time of the analysis.
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4.2 Eligibility Criteria
Eligible patients had a complete rupture of the Achilles tendon that had taken place 
within 14 days of visiting our facility, were between the ages of 18 and 70 years, could 
speak and understand the English language and agreed to follow the recommended 
rehabilitation protocol. Patients with a significant ipsilateral injury (femur or tibia 
fracture), open injury of the Achilles tendon, fluroquinolones-associated rupture (within 
two weeks of injury), and avulsion of Achilles tendon from calcaneus were also 
excluded. Patients who were pregnant, who had any neurological, collagen, peripheral 
vascular disease (stroke, cerebral palsy, Ehlers-Danlos), or diabetes were also excluded.
4.3 Treatment protocol
All patients (including those in the historical control group) were placed in a removable 
below knee orthosis (Aircast™ pneumatic walking brace, Figure 2) either at the 
emergency room or at the initial clinic visits. The Aircast™ brace contained a two cm 
heel lift providing approximately 20° of plantar flexion within the Aircast™ brace to 
encourage repair of the tendon fibers in an optimal position. We instructed patients to 
remain non-weight bearing and to use crutches until approximately four to six weeks post 
injury. Patients were to remain in the Aircast™ brace during all activities of daily living 
with the exception of bathing.







Figure 2 AircastIM orthosis
4.4 Autologous Conditioned Plasma (ACP) -  Prospective Cohort 
Only
We drew approximately 12ce's of blood from the patient’s arm, which was then placed in 
an Arthrex ACP® double syringe system and spun in a table-top Rotafix 32A centrifuge 
(Fig 3) at 1500 rpm for five minutes. This process separated the blood components from 
the plasma components into a visible three-layer consistency of red blood components 
(bottom), a very thin milky white leukocyte component (middle), and yellow plasma 
components (top) (Fig 4). The physician (KW) then pulled back on the syringe and 
extracted only the plasma. The amount of plasma retrieved was between three and four 























The surgeon (KW) palpated and marked the gap in the ruptured Achilles tendon, then 
sterilized and prepped the area for injection. He injected a numbing agent of Lidocaine 
(2% concentration) superficially into the area. This was followed immediately by the 
ACP® injection at the tendon gap. The second injection of ACP®, given two weeks 
later, followed an identical procedure.
4.5 Physical Therapy Protocol
All patients (including the historical control group) were given a prescription to begin 
physiotherapy at four weeks post injury at the clinic of their choice. We provided an 
instruction sheet that detailed the rehabilitation protocol.
The protocol suggested that at two to four weeks post injury, patients could begin active 




control swelling, knee/hip exercises as appropriate, non-weight bearing fitness or cardio 
work, and hydrotherapy within motion and weight bearing limitations. At four to six 
weeks activities were progressed to weight bearing as tolerated and exercises continued 
as in week’s two to four. At weeks six through eight, exercises continued to include 
weight bearing as tolerated, with the addition of slow dorsi flexion stretches, graduated 
resistance exercises (open kinetic chain, closed kinetic chain, and functional), 
proprioceptive and gait training. At eight weeks, the patient was weaned off the boot, and 
continued to progress through range of motion, strength, proprioceptive, power, 
endurance, increased dynamic weight bearing exercises, plyometric training, and sport- 
specific retraining. For the exact physical therapy protocol, please refer to Willits et al
(2010)112. J
— m
Patients returned for isokinetic strength testing, range of motion, calf circumference, i
3Ankle-Hindfoot AOFAS scores, and Leppilahti scores at six months and one year post ■
3<injury.
4.6 Primary Outcome -  Isokinetic Strength
75We chose to measure isokinetic strength, which has been shown to be reliable (ICCs for 
plantar flexion concentric strength with hip flexion 110° and knee flexion 90° were 0.66- 
0.95).
Strength was measured using a Biodex Multi-Joint System 3 Dynamometer (Biodex 
Medical, Shirley, NY) (Figure 5). We positioned the patient sitting with the hip flexed at 
45°, and the knee flexed at about 30° so that the tibia and fibula were parallel to the
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ground. The thigh was supported in a thigh rest and strapped in place to prevent its use 
during the testing. The medial malleolus was aligned with the dynamometer's axis of 
rotation and the foot was fixed to the dynamometer footplate via two Velcro straps and a 
modified ankle strap for added ankle stability. The isokinetic strength tests were 
performed by three researchers who all received the same training.
Figure 5 Biodex Dynamometer
For familiarization, patients performed submaximal practice actions at the beginning of 
every testing velocity set. Participants performed three different test velocities for each 
ankle that included four concentric isokinetic contractions of plantar and dorsi flexion 
with maximum effort at 30°/s and 60°/s, and 10 concentric isokinetic contractions at 
2407s. One minute rest was given between each test velocity. The testing was done 







Peak plantar and dorsi flexion torque (N-m) were calculated by averaging peak torque 
values of the contractions collected at each velocity.
4.7 Secondary Objectives
4.7.1 Leppilahti scores
The Leppilahti score is a disease-specific functional outcome measure that includes 
patient ratings of pain, stiffness, calf muscle weakness, footwear restrictions, range of 
motion and progress satisfaction. The isokinetic strength measures used as our primary 
objective, including plantar and dorsi flexion at speeds of 307s, 607s and 2407s, are 
included in the traditional scoring of the Leppilahti scale. The minimum score is 0 and 
the maximum score is 100 where 100 is the best possible score.
4.7.2 Range of motion
Plantar flexion and dorsi flexion were measured using a standard goniometer with the 
patient sitting on a plinth with their legs hanging relaxed over the edge of the exam table 
so that the knees were flexed at 90°. We then placed the ankle in a neutral position of 
approximately 90°.
The axis of rotation was the point just inferior to the lateral malleolus, and the long axis 
of the fibula was used as the fixed lever arm. The moving lever arm was lined up with the 
length of the fifth metatarsal. We instructed the patient to move into plantar or 
dorsiflexion and the lever arm was moved accordingly to record the amount of movement
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in degrees in relation to the neutral position. This method of measurement has been 
shown to be reliable (ICC=0.71-0.91 )7'\
4.7.3 Calf Circumference
Calf circumference was measured with the patient sitting at the edge of the plinth with 
the lower legs relaxed. We used a standard tape measure to measure the circumference of 
the calf in centimeters from approximately 15 centimeters distal to the inferior pole of the 
patella, the area of largest muscle bulk in the gastrocnemius. This method of 
measurement has been shown to be reliable (ICC = 0.97-0.98 )7\
Mi
Mi
4.7.4 Ankle-Hindfoot Scale (AOFAS) »
3
The Ankle-Hindfoot Scale (AOFAS) is a region-specific quality of life and objective
3
functional scale. It accounts for pain, function in activities of daily living, quality of -
range of motion and stability, and ankle alignment. It is a combination of subjective j!
grading from the patient and objective evaluation by the physician. The questionnaire
consisted of three sections, which accounted for pain (one item of 40 points), function
(seven items of total 50), and alignment (one item of 10 points). Higher scores represent
better outcomes. For function, four of the items were subjectively answered by the patient
and three were objective evaluations by the physician. Alignment was also evaluated by
the physician. The AOFAS has demonstrated concurrent validity32,41, criterion validity41,
adequate construct validity97, and test-retest reliability41. The non-ACP® historical cohort
did not complete this form, and so these data are presented for the prospective cohort
only.
There were 72 patients in the control group of the randomized trial published by Willits 
et al (2010)112. Thirty-four patients had complete strength data which included seven 
imputed, and were used in our analysis. We recruited 73 patients into the prospective 
cohort study; 51 of these patients had complete data at one-year post-injury and were 
used in the analysis. Given a conventional Type I error rate of 5%, we had about 66% 
power to detect a moderate effect size of 0.5 standard deviation, which has been 
suggested to represent a minimal detectable change . Given the same parameters, we 
have 80% power to detect difference as small as 0.59 standard deviation.
We used independent-group t tests to make between group statistical comparisons, in 
which the independent variable was the group and the dependent variable was the 
continuous outcome measure (i.e., strength, Leppilahti score, ankle range of motion, or 
calf circumference) at one year after treatment. A p value of less than 0.05 was 
considered significant. Outcome data for each group are presented as the mean and 
standard deviation, and the mean difference between groups and the 95% confidence 
interval (Cl) are provided. Patients who withdrew from the study because they had 
moved or who had been lost to follow-up, were excluded from the analysis. It was 
believed that patients who had moved represented data that were missing completely at 
random and therefore would not threaten the validity of the estimate of the treatment 
effect.
For missing strength data in our historical cohort, we completed a paired samples t-test 
and an intraclass correlation (ICC) to determine if we could impute data from the two
5 Chapter 5: Statistical Analysis
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year time point into our missing data points at one year. The paired samples t-test showed 
no statistically significant difference between groups, but the ICC showed no correlation 
between the complete data at one year and two year time points. We then applied a 
regression method that accounted for gender, weight, age, two year strength scores, 
activity at injury, and calf circumference of the involved leg. We were able to impute 
data at various speeds for missing strength scores. Our analysis included 34 patients from 






6 Chapter 6: Results
Between 2008 and 2010, we screened 83 patients. Of these, 10 were excluded; one who 
refused the injection, three patients had diabetes, two were older than 70 years, two 
patients had an injury that occurred longer than two weeks prior, and two patients were 
excluded because they had an incomplete rupture. A total of 73 patients were entered into 
our prospective study. Since that time, nine patients were lost to follow-up, one withdrew 
because of wait time at their appointment, and eight patients were unavailable for their 
one year visit due to unavailability to attend appointment because of work commitment 
or unable to be reached. The eight who were unavailable were able to attend later 
appointments in the study at 18 months and two years post-injury. Of the remaining 55 
patients, two patients re-ruptured their Achilles tendon, one ruptured their contra-lateral 
side, and one patient had not yet reached their one year time point at the time of this 
analysis. Thus 51 patients with one year data from the ACP group was entered into our 
analysis of the data.
In the historical cohort at one year, we had complete strength data for 27 patients and 
imputed data for another seven patients so that we had 34 patients with strength data at 
one year (See Fig 6). There were three re-ruptures.
Patients were balanced between groups for characteristics of gender, age, weight, height 
and activity at time of injury (See Table 2). The average number of days post-injury that 
the first ACP injection was given was 8.3 days (range 2-20 days).
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Figure 6 Flow diagrams of patient participation and data
Table 2 Demographics
Characteristics ACP® (n = 51) Non-ACP® (n = 34)
Gender (male : female) 43 : 8 29: 5
Age* (years) 41.5 ± 11.1 40.2 ±8.1
Height* (cm) 178.6 ±9.2 178.1 ± 10.1
Weight* (kg) 88.5 ±18.3 87.1 ± 16.4
Activity at injury (no. of ADL4 8, Sports 42 ADL 6, Sports 28
patients)
*M ean ±  S ta n d a rd  d e v ia tio n
yA D L  =  a c tiv i t ie s  o f  d a ily  liv in g
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6.1 Primary objective results
The mean isokinetie plantar flexion strength ratio (Figure 7) at 307s for the ACP group 
was 87.5% (± 19.6%) and 90.5% (± 30.1%) for the historical control group. The mean 
between group difference was -2.9% (95% Cl -13.6 to 7.8), p = 0.6. The mean isokinetic 
plantar flexion strength ratio at 607s in the ACP group was 90.1% (± 23.6%) and 90.4% 
(± 38.1%) for the historical control group. The mean between group difference was -0.3% 
(95% Cl -13.6 to 13.0), p = 1.0. The mean isokinetic plantar flexion strength ratio at 
2407s in the ACP group was 85.0% (± 17.8%) and 82.3% (± 27.2%) for the historical 
control group. The mean between group difference was 2.7% (95% Cl -7.0 to 12.4), p = 
0.6.








6.2 Secondary objective results
Comparison of between group’s side-to-side differences in plantar flexion range of 
motion (ROM) where the uninjured side had greater range in both groups, was -1.1° (± 
9.3°) for the ACP® group and -2.6° (± 4.6°) for the historical control group. The mean 
difference between groups was 1.5° (95% Cl -1.9 to 4.9), p = 0.4. Comparison of 
between group’s side-to-side differences in dorsi flexion range of motion (ROM) where 
the uninjured side also had greater range in both groups, -0.9° (± 5.3) for the ACP® 
group and -1.4° (± 2.8°) for the historical control group. The mean difference between 
groups was 0.6° (95% Cl -1.4 to 2.5), p = 0.6.
At one year, measured side to side difference in calf circumference in the ACP® group 
was -1.6cm (±1.2) and -1.6cm (± 2.0) for the historical control group, where the 
uninjured side had greater calf circumference in both groups. The mean difference 
between groups was -0.02 (95% Cl -0.7 to 0.7), p = 1.0.
The final scores for the Leppilahti quality of life questionnaire produced a mean of 81.2 
(± 11.6) points for the ACP group and 78.1 (± 14.4) points for the historical control 




The ankle-hindfoot AOFAS scores for the ACP® group are displayed in Table 3. As 
expected, patients demonstrated the greatest improvement in the function domain over 
one year. Higher scores indicate improved results.
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Table 3 AOFAS ankle-hindfoot scores
Item Mean ± SD 95% Cl
Pain (40 points)
6 Weeks 33.9 (5.4) 32.2-35.5
3 Months 30.9 (6.4) 29.0-32.9
6 Months 33.6 (5.7) 31.9-35.4
1 Year 36.4 (4.9) 34.9-37.8
Function (50 points)
6 Weeks 35.0 (7.6) 32.7-37.3
3 Months 41.8 (5.8) 40.0-43.6
6 Months 46.4 (2.7) 45.6-47.2
1 Year 49.0(1.4) 48.5 -  49.4
Alignment (10 points)
6 Weeks 9.8(1.1) 9.5 -  10.2
3 Months 10(0)
6 M o n th s 10(0)
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1 Year 9.7 (1.5) 9 .2 -  10.1
Total Score (100 points)
6 Weeks 78.7 (10.3) 75.6-81.8
3 Months 82.7 (9.8) 79.7-85.7
6 Months 90.1 (6.3) 88.1 -92 .0
1 Year 95.0(5.6) 93.3 -  96.7
Note: Data includes the patient who ruptured her contra-lateral side
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7 Chapter 7: Discussion
The use of ACP in orthopedic injuries is a relatively new concept. The literature is 
limited on its use, specifically in tendon healing. Some in v ivo  and in v itro  cell culture 
studies7' 45' 96' 1(15 have shown ACP to he a significant activator of circulation-derived cells 
for enhancement of the initial tendon healing process. This benefit has not yet been 
demonstrated in the clinical setting.
In our study we found no statistically significant differences in any of our comparisons 
of the prospective ACP® and historical non-ACP® groups including calf circumference, 
range of motion (plantar and dorsi flexion), isokinetic strength (30°/sec, 60°/sec, 
240°/sec), or Leppilahti scores. We ran the isokinetic strength analysis without the 
imputed data (n = 27) in our historical control and still found no statistically significant 
differences between groups.
There were two re-ruptures in the ACP® group and three in the historical non-ACP® 
group (OR = 0.65, 95% Cl 0.11 to 4.00; p = 0.64). Our re-rupture rate is similar to that 
observed in studies that report the re-rupture rate in operatively treated patients ’ ’ ’ 
We did not observe any major complications in either group.
The rehabilitation protocol employed in both groups in our study included early weight 
bearing with crutches in a below-knee orthosis. Our protocol was the same as our 
historical group, and the decision of the historical study by Willits et al (2010) to move 
patients from immobilization to early mobilization was influenced by the work of Saleh 
et al (1992)86, Gelberman et al (1990)31, McComis et al (1997)70, Maffulli et al (2003)61,
and Costa et al (2006) . These studies showed evidence for spontaneous healing of 
tendons without immobilization. There is evidence suggesting that early functional 
mobilization may offer patients greater functional outcome following Achilles tendon 
rupture' . In fact, Willits et al (2010) conducted a systematic review with meta­
analysis and showed that for those studies where early mobilization was included as part 
of the rehabilitation protocol, the re-rupture rate in non-operatively treated patients was 
similar to that observed for operatively treated patients.
The concentration of PRP obtained in our study through the Arthrex double-syringe 
system is two to three times the concentration of platelets in baseline blood. This 
concentration has been found effective in in v itro  and in v ivo  studies in effective 
proliferation and angiogenesis of tissue17' 69, despite claims that higher concentrations 
may have a greater effect77' 111.
First, Choi et al (2005) showed evidence of effective cellular viability and proliferation 
with PRP concentrations of two to three times (1% to 5%) baseline blood, in their in vitro 
study on bone cells. They compared various concentrations of PRP, platelet poor plasma 
(PPP), and platelet concentrate on bone cells and noted the increase of cells after seven to 
14 days. The lower concentrations of PRP showed a significant increase in proliferative 
cells (p < 0.05), whereas greater concentrations of up to 100% approached a toxic effect 
on cells.
Second, Mastrangelo et al (2011)69 found concentrations of plasma three times found in 
baseline blood when compared to that of a five times concentration, did not significantly 
harm the mechanical outcomes of their anterior cruciate ligament animal model. There
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were no significant differences in joint laxity at 30° (p = 0.14) and 90° (p = 0.76) of knee 
flexion, but there was a significant difference at 60° (p = 0.01) favorable to the three 
times concentration. There was also no significant difference in the structural properties 
of the tendons (p > 0.05). The impact of the concentration of platelets on the outcome of 
this study is uncertain. Thus, we are uncertain whether the concentration of PRP in our 
study explains the lack of effectiveness that was observed.
7.1 Limitations
A limitation to this study is its retrospective design. However, the historical cohort group 
that we selected was part of a randomized study that was led by the same authors. Thus, 
unlike most retrospective designs, we are certain that eligibility criteria, protocols for 
measuring outcomes and conservative treatment methods were similar between studies.
Another limitation to this study is the limited amount of patient data available to compare 
at one year. Specifically, in our prospective cohort, 29% of our patients had incomplete 
data. It is possible that patients with missing data are different from those with complete 
data increasing the potential for a biased estimate of the treatment effect. However, of 
the 21 patients with incomplete data, 8 were missing for random reasons, which in 
unlikely to bias the results.
In our historical control, we imputed strength data for 7 patients at one year post injury. 
To determine the validity of our imputation method, we calculated a paired t-test to 
measure the magnitude of any systematic difference between one and 2 year strength data 
and an ICC to measure the magnitude of the agreement between these two strength
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measurements. The paired t-test found no statistically significant systematic difference 
between time points, but the ICC demonstrated low agreement between the time points 
(range 0.29 to 0.67). Thus, we could not impute the missing one year strength data using 
the available two year data. We then used a regression method adjusting for sex, weight, 
age, two year strength scores, activity at injury, and calf circumference of the involved 
leg, which showed a reasonable ability to predict the one year strength value (R“= 0.3). 
Finally, we conducted the analysis with and without the imputed values and found that 
the estimate of effect was similar and none of the conclusions changed.
We used the Leppilahti scale as an outcome score even though it is not a validated 
outcome measure for Achilles tendon rupture. However, using this scale was necessary 
because it was used in the randomized trial from which we obtained our historical cohort. 
Further, the Leppilahti scale was the only available outcome measure for Achilles tendon 
rupture at the time the randomized trial (and thus historical control group) data was being 
collected. For our prospective cohort we also collect the AOFAS, which is a valid scale 
for Achilles tendon rupture.
Patient adherence to the physiotherapy protocol was not monitored, and patients were 
allowed to choose their place of treatment. As the early functional rehabilitation protocol 
played an important role in the progression of the patient, it may have affected their 
outcomes. However, because we are certain that the study design, data collection 
protocols and rehabilitation protocols were the same between our prospective cohort and 
the historical cohort; we have no reason to believe that the rate or degree of compliance
would differ between groups.
Ankle range of motion was measured with the patient in sitting with the knee at 90° 
flexion. This could be considered a limitation as it would isolate the active range of 
motion recorded to the action of the soleus muscle, and does not include the 
gastrocnemius muscle.
7.2 Strengths
Despite the fact that the study has a retrospective design, we are certain that selection bias 
(perhaps the largest potential source of bias in non-randomized designs) did not occur 
since the historical control group was part of a randomized trial and both studies recruited 
consecutive patients. The consecutive recruitment of patients also gives us a certainty that 
our population is reflective of the type of patient with this injury.
This study was the first to compare the use of ACP® in the Achilles tendon model with 
accelerated functional rehabilitation and with a patient inclusion of its size.
7.3 Summary
The results of this clinical trial suggests there is no measurable clinical benefit to the 
addition of autologous conditioned plasma (ACP®) to the treatment regimen for non- 
operatively treated acute Achilles tendon rupture with accelerated functional 
rehabilitation. Suggestions for further studies include a randomized controlled trial, the 
use of the validated Achilles tendon rupture score (ATRS), eccentric measurement of 
isokinetic strength, and a more functional strength outcome measure such as tiptoe 
scoring. Other suggestions for future research include the use of a PRP system that yields 
a higher concentration of platelets and ACP® injections administered closer to the date of
injury during the initial inflammation healing phase, as opposed to the proliferative 
phase, which may have happened in some of our patients.
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Inclusion Criteria
•  Complete Achilles tendon tear
•  Within 14 days of injury
•  18-70 years of age
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